AxoGen, Inc. (NASDAQ:AXGN) Given Consensus Rating of “Buy” by Brokerages

Shares of AxoGen, Inc. (NASDAQ:AXGN) have received an average recommendation of “Buy” from the four analysts that are currently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $20.75.

A number of research firms recently issued reports on AXGN. Lake Street Capital began coverage on AxoGen in a report on Monday. They set a “buy” rating and a $30.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $24.00 price objective on shares of AxoGen in a report on Wednesday, March 5th. Finally, Canaccord Genuity Group increased their price objective on AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, February 26th.

AxoGen Trading Up 0.8 %

NASDAQ:AXGN traded up $0.13 during mid-day trading on Monday, hitting $17.38. The company had a trading volume of 12,653 shares, compared to its average volume of 536,552. AxoGen has a fifty-two week low of $5.55 and a fifty-two week high of $21.00. The business’s fifty day moving average is $18.01 and its two-hundred day moving average is $15.50. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. The firm has a market cap of $770.70 million, a P/E ratio of -54.38 and a beta of 1.02.

Insider Buying and Selling

In other AxoGen news, Director Amy Mcbride Wendell sold 5,000 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $20.02, for a total transaction of $100,100.00. Following the transaction, the director now owns 97,899 shares in the company, valued at $1,959,937.98. This trade represents a 4.86 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 7.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On AxoGen

Hedge funds and other institutional investors have recently modified their holdings of the business. R Squared Ltd bought a new position in shares of AxoGen in the 4th quarter valued at $30,000. US Bancorp DE bought a new stake in AxoGen during the 4th quarter worth $30,000. State of Wyoming bought a new stake in AxoGen during the 4th quarter worth $31,000. Quest Partners LLC grew its position in AxoGen by 23,066.7% during the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 2,076 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new stake in AxoGen during the 4th quarter worth $93,000. Institutional investors own 80.29% of the company’s stock.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.